Table 3 Observed cancer cases for the male Lynch syndrome cohort with 100% or 50% probability of MMR mutation (excluding colorectal and endometrial cancer)
From: A retrospective study of extracolonic, non-endometrial cancer in Swedish Lynch syndrome families
Primary cancer | Observed number | Proportion [%] | LL 95% | UL 95% | Proportion [%] in Sweden 1970 | Proportion [%] in Sweden 2010 | Reference outside CI |
|---|---|---|---|---|---|---|---|
Stomach | 38 | 18.36 | 13.04 | 23.67 | 8.84 | 1.76 | above |
Prostate | 38 | 18.36 | 13.04 | 23.67 | 10.82 | 26.47 | No |
Kidney and urinary tract excl prostate | 34 | 16.43 | 11.59 | 21.74 | 13.05 | 8.75 | No |
Brain and nervous system | 19 | 9.18 | 5.31 | 13.04 | 7.94 | 5.66 | No |
Skin excl melanoma | 13 | 6.28 | 3.38 | 9.66 | 2.44 | 5.24 | No |
Pancreas | 12 | 5.8 | 2.9 | 9.18 | 3.36 | 1.74 | No |
Malignant melanom | 9 | 4.35 | 1.93 | 7.25 | 5.19 | 10.35 | No |
Blood and lymphatic tissue | 9 | 4.35 | 1.93 | 7.25 | 12.53 | 12.3 | below |
Small bowel | 7 | 3.38 | 0.97 | 5.8 | 0.75 | 0.77 | above |
Liver and biliary system | 6 | 2.9 | 0.97 | 5.31 | 2.44 | 2.04 | No |
Lung and airways | 5 | 2.42 | 0.48 | 4.83 | 11.38 | 5.51 | below |
Oesophagus | 4 | 1.93 | 0.48 | 3.86 | 1.22 | 0.93 | No |
Head and neck | 3 | 1.45 | 0 | 3.38 | 5.76 | 4.04 | below |
Bone and soft tissue | 3 | 1.45 | 0 | 3.38 | 2.1 | 1.52 | No |
Testicle | 2 | 0.97 | 0 | 2.42 | 3.43 | 6.54 | below |
Breast | 1 | 0.48 | 0 | 1.45 | 0.33 | 0.28 | No |
Penis | 1 | 0.48 | 0 | 1.45 | 0.66 | 0.37 | No |
Thyroid | 1 | 0.48 | 0 | 1.45 | 1.13 | 1.37 | No |
Eye | 0 | 0 | 0 | 0 | 0.58 | 0.44 | below |
Endocrine cancer | 0 | 0 | 0 | 0 | 2.57 | 1.91 | below |
Unspecified location | 0 | 0 | 0 | 0 | 3.45 | 2.01 | below |